Department of Radiology, Hospital Universitari Son Espases, Palma de Mallorca, Spain.
Department of Gastroenterology, Hospital Universitari Son Espases, Palma de Mallorca, Spain.
Diagn Interv Radiol. 2019 Sep;25(5):346-352. doi: 10.5152/dir.2019.18416.
We aimed to retrospectively evaluate the long-term clinical and patency results after the placement of transjugular intrahepatic portosystemic shunts (TIPS) using stent-graft. Many studies show the clinical results and the patency follow-up of TIPS with stent-graft in the short and medium term. However, few studies show long-term results.
Between 2002 and 2016, TIPS with stent-grafts were placed in 132 patients. The median age was 59.5 years. The median Model for End-stage Liver Disease (MELD) score was 13, and 71% were Child-Pugh B. Indications for TIPS were bleeding (83%) and ascites or hydrothorax (17%). The technical and clinical success rates were calculated, as were the rates of patency, survival and complications. The median follow-up period was 43 months.
The technical success rate was 98%, and the clinical success rates were 85% in patients with indication for bleeding and 95% in patients with indication for ascites or hydrothorax. Primary patency did not decrease from 66% after 6 years (95% confidence interval [CI], 56.2%-75.8%) primary assisted patency remained stable at 87% after 6 years (95% CI, 77.2%-96.8%) and secondary patency did not decrease from 98% after 4 years (95% CI, 95.1%-100%). The median overall survival was 42.8 months (95% CI, 33.8-51.8 months). A total of 54 patients suffered some type of complication, minor (28 patients) or major (26 patients), during the follow-up.
The clinical success rate was high. The choice of the maximum initial limit of portosystemic gradient and the diameter of the post-TIPS shunt, together with the number of shunt reductions, are important to be able to compare results between publications. In our study, the patency rates did not decrease after 6 years; hence, long-term follow-up of these patients may not be necessary.
我们旨在回顾性评估使用支架-移植物经颈静脉肝内门体分流术(TIPS)的长期临床和通畅率结果。许多研究显示了 TIPS 支架-移植物在短期和中期的临床结果和通畅率随访。然而,很少有研究显示长期结果。
在 2002 年至 2016 年期间,对 132 例患者进行了 TIPS 支架-移植物置入术。中位年龄为 59.5 岁。中位终末期肝病模型(MELD)评分为 13,71%为 Child-Pugh B 级。TIPS 的适应证为出血(83%)和腹水或胸水(17%)。计算了技术和临床成功率、通畅率、生存率和并发症发生率。中位随访时间为 43 个月。
技术成功率为 98%,出血适应证患者的临床成功率为 85%,腹水或胸水适应证患者的临床成功率为 95%。6 年后,初始通畅率未下降至 66%(95%置信区间[CI]:56.2%-75.8%),辅助初始通畅率在 6 年后保持稳定在 87%(95%CI:77.2%-96.8%),继发性通畅率未从 4 年后的 98%下降(95%CI:95.1%-100%)。中位总生存率为 42.8 个月(95%CI:33.8-51.8 个月)。在随访期间,共有 54 例患者发生某种类型的并发症,轻微(28 例)或严重(26 例)。
临床成功率较高。选择最大初始门体系统梯度限制和 TIPS 后分流直径以及分流减少数量对于能够比较文献之间的结果非常重要。在我们的研究中,6 年后通畅率没有下降;因此,对这些患者进行长期随访可能不是必要的。